Variable drug metabolism genes in Arab population

Pharmacogenomics Journal

Volumn 4, Issue 4, 2004, Pages 260-266

  Bu, R ^a   Gutierrez M I ^a   Al Rasheed, M ^a   Belgaumi, A ^a   Bhatia, Kishor ^a,b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Intl Network Cancer Treatment/Res   (Belgium)

Author keywords

CYP1A1; Genetic polymorphism; GSTs; MTHFR; MTR (MS); NAT2; NQO*1; Population genetic structure; Risk of cancer; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACYLTRANSFERASE; ADENINE; CYTOCHROME P450 1A1; CYTOSINE; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE; GUANINE; METHIONINE SYNTHASE; OXIDOREDUCTASE; THYMINE;

ACETYLATOR PHENOTYPE; ADULT; AFRICA; ARAB; ARTICLE; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; WILD TYPE;

AFRICAN CONTINENTAL ANCESTRY GROUP; ARABS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYMES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; SAUDI ARABIA; VARIATION (GENETICS);

EID: 4344639877     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500251     Document Type: Article

References (43)

1. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100: 3832-3834.
2. Sekine I, Saijo N. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann Oncol 2001; 12: 1515-1525.
3. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99: 754-758.
4. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8658.
5. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nat Rev Cancer 2001; 1: 99-108.
6. Nebert DW, McKinnon RA, Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996; 15: 273-280.
7. Krajinovic M, Labuda D, Mathonnet G, Labuda M, Moghrabi A, Champagne J et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002; 8: 802-810.
8. Krajinovic M, Labuda D, Sinnett D. Childhood acute lymphoblastic leukemia: genetic determinants of susceptibility and disease outcome. Rev Environ Health 2001; 16: 263-279.
9. Davies SM, Robison LL, Buckley JD, Tjoa T, Woods WG, Radloff GA et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia. J Clin Oncol 2001; 19: 1279-1287.
10. Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Welte K et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000; 10: 715-726.
11. Sabbagh N, Delaporte E, Marez D, Lo-Guidice JM, Piette F, Broly F. NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 1997; 7: 131-135.
12. Toffoli G, Cecchin E. Pharmacogenetics of stomach cancer. Suppl Tumori 2003; 2: S19-S22.
13. Chiusolo P, Reddiconto G, Casorelli I, Laurenti L, Sora F, Mele L et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002; 13: 1915-1918.
14. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 2001; 10: 1239-1248.
15. Robien K, Ulrich CM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 2003; 157: 571-582.
16. Nebert DW, Roe AL, Vandale SE, Bingham E, Oakley GG. NAD(P)H:-quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med 2002; 4: 62-70.
17. Chabner BA. Cytotoxic agents in the era of molecular targets and genomics. Oncologist 2002; 7: 34-41.
18. Sawyer MB, Innocenti F, Das S, Cheng C, Ramirez J, Pantle-Fisher FH et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin Pharmacol Ther 2003; 73: 566-574.
19. Perentesis JP. Genetic predisposition and treatment-related leukemia. Med Pediatr Oncol 2001; 36: 541-548.
20. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002; 94: 1635-1640.
21. Allan JM, Wild CP, Rollinson S, Willett EV, Moorman AV, Dovey GJ et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA 2001; 98: 11592-11597.
22. Naoe T, Takeyama K, Yokozawa T, Kiyoi H, Seto M, Uike N et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000; 6: 4091-4095.
23. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54: 4313-4320.
24. Yuan ZM, Smith PB, Brundrett RB, Colvin M, Fenselau C. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. Drug Metab Dispos 1991; 19: 625-629.
25. Lisowsky I. High capacity binding by glutathione S-tranferases and glucocorticoid resistance. In: Tew KD, Pickett CB, Mantle TJ, Mannervik B, Hayes JD (eds). Structure and Function of Glutathione Transferases. CRC Press: Boca Raton, FL 1993; pp 199.
26. Celander M, Hahn ME, Stegeman JJ. Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. Arch Biochem Biophys 1996; 329: 113-122.
27. Celander M, Weisbrod R, Stegeman JJ. Glucocorticoid potentiation of cytochrome P4501A1 induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin in porcine and human endothelial cells in culture. Biochem Biophys Res Commun 1997; 232: 749-753.
28. Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 2001; 29: 596-600.
29. Lucotte G, Loirat F, Hazout S. Pattern of gradient of apolipoprotein E allele *4 frequencies in western Europe. Hum Biol 1997; 69: 253-262.
30. Haase D, Binder C, Bunger J, Fonatsch C, Streubel B, Schnittger S et al. Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk Res 2002; 26: 249-254.
31. Thier R, Bruning T, Roos PH, Rihs HP, Golka K, Ko Y et al. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int J Hyg Environ Health 2003; 206: 149-171.
32. Migliore L, Coppede F. Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res 2002; 512: 135-153.
33. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14: 567-572.
34. Matsuo K, Suzuki R, Hamajima N, Ogura M, Kagami Y, Taji H et al. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 2001; 97: 3205-3209.
35. Welfare M, Monesola Adeokun A, Bassendine MF, Daly AK. Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 289-292.
36. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999; 93: 1496-1501.
37. Cascorbi I, Brockmoller J, Mrozikiewicz PM, Bauer S, Loddenkemper R, Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 1996; 56: 3961-3966.
38. Cotton SC, Sharp L, Little J, Brockton N. Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000; 151: 7-32.
39. Coughlin SS, Hall IJ. Glutathione S-transferase polymorphisms and risk of ovarian cancer: a HuGE review. Genet Med 2002; 4: 250-257.
40. Brockton N, Little J, Sharp L, Cotton SC. N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol 2000; 151: 846-861.
41. Botto LD, Yang Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000; 151: 862-877.
42. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999; 96: 12810-12815.
43. Song C, Xing D, Tan W, Wei Q, Lin D. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 2001; 61: 3272-3275.